Bcl-2 inhibitors: small molecules with a big impact on cancer therapy (original) (raw)

• Hanahan D, Weinberg RA . The hallmarks of cancer. Cell 2000; 100: 57–70.
  Article CAS Google Scholar
• Bratton SB, Cohen GM . Apoptotic death sensor: an organelle's alter ego? Trends Pharmacol Sci 2001; 22: 306–315.
  Article CAS Google Scholar
• Danial NN, Korsmeyer SJ . Cell death: critical control points. Cell 2004; 116: 205–219.
  Article CAS Google Scholar
• Adams JM, Cory S . The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324–1337.
  Article CAS Google Scholar
• Cory S, Adams JM . The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647–656.
  Article CAS Google Scholar
• Youle RJ, Strasser A . The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47–59.
  Article CAS Google Scholar
• Huang DC, Strasser A . BH3-Only proteins-essential initiators of apoptotic cell death. Cell 2000; 103: 839–842.
  Article CAS Google Scholar
• Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393–403.
  Article CAS Google Scholar
• Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294–1305.
  Article CAS Google Scholar
• Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315: 856–859.
  Article CAS Google Scholar
• Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A . Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007; 117: 112–121.
  Article CAS Google Scholar
• Miyashita T, Reed JC . Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151–157.
  CAS PubMed Google Scholar
• Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ . bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991; 67: 879–888.
  Article CAS Google Scholar
• Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace Jr AJ . An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000; 60: 6101–6110.
  CAS PubMed Google Scholar
• Fry DC, Vassilev LT . Targeting protein-protein interactions for cancer therapy. J Mol Med 2005; 83: 955–963.
  Article CAS Google Scholar
• Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677–681.
  Article CAS Google Scholar
• Becattini B, Kitada S, Leone M, Monosov E, Chandler S, Zhai D et al. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem Biol 2004; 11: 389–395.
  Article CAS Google Scholar
• Chan SL, Lee MC, Tan KO, Yang LK, Lee AS, Flotow H et al. Identification of chelerythrine as an inhibitor of BclXL function. J Biol Chem 2003; 278: 20453–20456.
  Article CAS Google Scholar
• Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 2001; 3: 173–182.
  Article CAS Google Scholar
• Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M . Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 2003; 46: 4259–4264.
  Article CAS Google Scholar
• Mohammad R, Giri A, Goustin AS . Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer. Recent Patents Anticancer Drug Discov 2008; 3: 20–30.
  Article CAS Google Scholar
• Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007; 104: 19512–19517.
  Article CAS Google Scholar
• Tang G, Yang CY, Nikolovska-Coleska Z, Guo J, Qiu S, Wang R et al. Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins. J Med Chem 2007; 50: 1723–1726.
  Article CAS Google Scholar
• Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421–3428.
  Article CAS Google Scholar
• Tzung SP, Kim KM, Basanez G, Giedt CD, Simon J, Zimmerberg J et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 2001; 3: 183–191.
  Article CAS Google Scholar
• Wang G, Nikolovska-Coleska Z, Yang CY, Wang R, Tang G, Guo J et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006; 49: 6139–6142.
  Article CAS Google Scholar
• Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000; 97: 7124–7129.
  Article CAS Google Scholar
• Wilson WH, Tulpule A, Levine AM, Dunleavy K, Krivoshik AP, Hagey AE et al. A phase 1/2a study evaluating the safety, pharmacokinetics and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. Blood 2007; 110: Abstract 1371.
• Zhang M, Ling Y, Yang CY, Liu H, Wang R, Wu X et al. A novel Bcl-2 small molecule inhibitor 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide (MNB)-induced apoptosis in leukemia cells. Ann Hematol 2007; 86: 471–481.
  Article CAS Google Scholar
• Bruncko M, Oost TK, Belli BA, Ding H, Joseph MK, Kunzer A et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem 2007; 50: 641–662.
  Article CAS Google Scholar
• Zhai D, Jin C, Satterthwait AC, Reed JC . Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 2006; 13: 1419–1421.
  Article CAS Google Scholar
• Verhaegen M, Bauer JA, Martin de la Vega C, Wang G, Wolter KG, Brenner JC et al. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 2006; 66: 11348–11359.
  Article CAS Google Scholar
• Mohammad R, Young D, Chen B, Aboukameel A, Chen J, Nikolovska-Coleska Z et al. ApoG2, a potent, non-toxic small-molecule inhibitor of Bcl-2 family: a preclinical trial in lymphoma. Proc Amer Assoc Cancer Res 2006; 47: Abstract 1335.
• Kutzki O, Park HS, Ernst JT, Orner BP, Yin H, Hamilton AD . Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry. J Am Chem Soc 2002; 124: 11838–11839.
  Article CAS Google Scholar
• Lee EF, Czabotar PE, Smith BJ, Deshayes K, Zobel K, Colman PM et al. Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ 2007; 14: 1711–1713.
  Article CAS Google Scholar
• Zhang YH, Bhunia A, Wan KF, Lee MC, Chan SL, Yu VC et al. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft. J Mol Biol 2006; 364: 536–549.
  Article CAS Google Scholar
• van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389–399.
  Article CAS Google Scholar
• Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 2008; 68: 3413–3420.
  Article CAS Google Scholar
• Chen S, Dai Y, Harada H, Dent P, Grant S . Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007; 67: 782–791.
  Article CAS Google Scholar
• Dai Y, Grant S . Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res 2007; 67: 2908–2911.
  Article CAS Google Scholar
• Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375–388.
  Article CAS Google Scholar
• Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA et al. ‘Seed’ analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-X(L) inhibitor ABT-737. Oncogene 2007; 26: 3972–3979.
  Article CAS Google Scholar
• Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007; 67: 1176–1183.
  Article CAS Google Scholar
• Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173–1186.
  Article CAS Google Scholar
• Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007; 14: 943–951.
  Article CAS Google Scholar
• Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007; 26: 2374–2380.
  Article CAS Google Scholar
• Kline MP, Rajkumar SV, Timm MM, Kimlinger TK, Haug JL, Lust JA et al. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 2007; 21: 1549–1560.
  Article CAS Google Scholar
• Trudel S, Stewart AK, Li Z, Shu Y, Liang SB, Trieu Y et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 2007; 13: 621–629.
  Article CAS Google Scholar
• Kohl TM, Hellinger C, Ahmed F, Buske C, Hiddemann W, Bohlander SK et al. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia 2007; 21: 1763–1772.
  Article CAS Google Scholar
• Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A . BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 2008; 111: 2300–2309.
  Article CAS Google Scholar
• Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A et al. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol 2008; 140: 181–190.
  CAS PubMed Google Scholar
• Vogler M, Dinsdale D, Sun XM, Young KW, Butterworth M, Nicotera P et al. A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ 2008; 15: 820–830.
  Article CAS Google Scholar
• Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 2008; 68: 2321–2328.
  Article CAS Google Scholar
• Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB et al. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res 2007; 13: 7191–7198.
  Article CAS Google Scholar
• Huang S, Sinicrope FA . BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res 2008; 68: 2944–2951.
  Article CAS Google Scholar
• Trump BF, Berezesky IK, Chang SH, Phelps PC . The pathways of cell death: oncosis, apoptosis, and necrosis. Toxicol Pathol 1997; 25: 82–88.
  Article CAS Google Scholar
• Tajeddine N, Galluzzi L, Kepp O, Hangen E, Morselli E, Senovilla L et al. Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 2008; 27: 4221–4232.
  Article CAS Google Scholar
• Li H, Chen Y, Jones AF, Sanger RH, Collis LP, Flannery R et al. Bcl-xL induces Drp1-dependent synapse formation in cultured hippocampal neurons. Proc Natl Acad Sci USA 2008; 105: 2169–2174.
  Article CAS Google Scholar
• Cheson BD . Oblimersen for the treatment of patients with chronic lymphocytic leukemia. Ther Clin Risk Manag 2007; 3: 855–870.
  CAS PubMed PubMed Central Google Scholar